Programmed cell death protein 1 activation preferentially inhibits CD28.CAR–T cells

• Published in: Cytotherapy (Oxford, England) Vol. 20; no. 10; pp. 1259 - 1266
• Main Authors: Zolov, Sergey N., Rietberg, Skyler P., Bonifant, Challice L.
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.10.2018
• Subjects: adoptive cell therapy; Advanced Basic Science; B7-H1 Antigen - genetics; B7-H1 Antigen - immunology; B7-H1 Antigen - metabolism; cancer immunotherapy; CD28 Antigens - genetics; CD28 Antigens - immunology; Cell Line, Tumor; chimeric antigen receptor–T cells; Cytotoxicity Tests, Immunologic - methods; Genetic Engineering; Hepatitis A Virus Cellular Receptor 2 - immunology; Hepatitis A Virus Cellular Receptor 2 - metabolism; Humans; immune checkpoint blockade; immune evasion; Immunotherapy, Adoptive - methods; Interleukin-3 Receptor alpha Subunit - genetics; K562 Cells; Leukemia, Myeloid, Acute - pathology; Leukemia, Myeloid, Acute - therapy; Lymphocyte Activation; Other; Programmed Cell Death 1 Receptor - immunology; Programmed Cell Death 1 Receptor - metabolism; Receptors, Antigen, T-Cell - metabolism; Receptors, Chimeric Antigen - genetics; Receptors, Chimeric Antigen - immunology; T-Lymphocytes - immunology; T-Lymphocytes - physiology; Tumor Microenvironment; immune evasion; chimeric antigen receptor–T cells; adoptive cell therapy; cancer immunotherapy; immune checkpoint blockade

Targeted adoptive immunotherapy with engineered T cells is a promising treatment for refractory hematologic malignancies. However, many patients achieving early complete remissions ultimately relapse. Immunosuppressive ligands are expressed on tumor and supportive cells in the tumor microenvironment...